

Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression

Breast Cancer Research and Treatment

Authors: Charlotte Levin Tykjær Jørgensen¹, Carina Forsare¹, Pär-Ola Bendahl¹, Anna-Karin Falck², Mårten Fernö¹, Kristina Lövgren¹, Kristina Aaltonen³, Lisa Rydén^{4,5}


Corresponding author: Charlotte Levin Tykjær Jørgensen, PhD

Address: Department of Clinical Sciences, Lund, Division of Oncology and Pathology, Medicon Village,
Building 404, Lund University, SE-22381 Lund, Sweden

Email: charlotte.levin_tykjaer_jorgensen@med.lu.se

Supplementary Figure 1 a-k. Kaplan-Meier survival curves showing distant recurrence-free interval (DRFi; years) in relation to epithelial-mesenchymal transition (EMT)-related marker and phenotype status in primary tumor and lymph node metastasis. E-cadherin (a-b), N-cadherin (c-d), twist (e-f), vimentin (g-h), EMT phenotype (i-j), EMT phenotype shift (k). *P* value from log rank test.


Abbreviations: EMT, epithelial-mesenchymal transition; PT, primary tumor; LNM, lymph node metastasis; DRFi, disease recurrence-free interval




PT

LN


e)




f)




g)




h)



i)



j)



k)

